You have 9 free searches left this month | for more free features.

tremelimumab

Showing 1 - 25 of 105

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 18, 2023

Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 27, 2022

Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)

Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 6, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed

Completed
  • Metastatic Breast Cancer
  • Brain radiotherapy or Stereotactic Radiosurgery
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 2, 2022

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Available
  • Unresectable Hepatocellular Carcinoma
  • (no location specified)
Aug 12, 2022

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Multiple Myeloma Trial in New York (Tremelimumab, Durvalumab, Prevnar-13)

Terminated
  • Multiple Myeloma
  • Tremelimumab
  • +3 more
  • New York, New York
  • +1 more
Oct 3, 2022

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Urothelial Carcinoma Trial in Amsterdam (Tremelimumab, Durvalumab, Paclitaxel)

Active, not recruiting
  • Urothelial Carcinoma
  • Tremelimumab
  • +2 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek Ziekenhuis
Jul 7, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

Recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • +3 more
  • Durvalumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

Nonsmall Cell Lung Cancer Trial in New York (Durvalumab, Tremelimumab)

Not yet recruiting
  • Nonsmall Cell Lung Cancer
  • New York, New York
    Columbia University Irving Medical Center
Apr 29, 2022

Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)

Completed
  • Endometrial Cancer
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Tumors Trial in Australia, Canada, United States (feladilimab, Tremelimumab, Docetaxel)

Completed
  • Neoplasms
  • Boston, Massachusetts
  • +7 more
Jul 28, 2022

Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)

Active, not recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
  • +1 more
Mar 22, 2022

Hepatocellular Carcinoma Trial in Toronto, Milan, Pamplona (Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tremelimumab
  • Toronto, Ontario, Canada
  • +2 more
Jun 27, 2022

Mesothelioma Trial in Houston (MEDI4736, Tremelimumab, no other name)

Active, not recruiting
  • Mesothelioma
  • Houston, Texas
    Baylor St Lukes
Jan 25, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage IV
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 21, 2022

Bladder Cancer, High-Risk Cancer, Tremelimumab Trial in Vancouver (Tremelimumab)

Recruiting
  • Bladder Cancer
  • +4 more
  • Tremelimumab
  • Vancouver, British Columbia, Canada
    Vancouver General Hospital
Nov 3, 2021

Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension Trial in Cincinnati (Durvalumab, Tremelimumab, Liver Transplant)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Cincinnati, Ohio
    University of Cincinnati
Dec 8, 2021

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma Trial in United States (Durvalumab, Tremelimumab)

Active, not recruiting
  • Germ Cell Tumor
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
May 2, 2022